[HTML][HTML] Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study
DF Archer, EA Stewart, RI Jain, RA Feldman… - Fertility and sterility, 2017 - Elsevier
Objective To evaluate the safety and efficacy of elagolix vs. placebo and elagolix with low-
dose E 2/progestogen add-back therapy. Design Proof-of-concept, dose-ranging, multiple …
dose E 2/progestogen add-back therapy. Design Proof-of-concept, dose-ranging, multiple …
Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study
DF Archer, EA Stewart, RI Jain… - Fertility and …, 2017 - mayoclinic.elsevierpure.com
Objective To evaluate the safety and efficacy of elagolix vs. placebo and elagolix with low-
dose E 2/progestogen add-back therapy. Design Proof-of-concept, dose-ranging, multiple …
dose E 2/progestogen add-back therapy. Design Proof-of-concept, dose-ranging, multiple …
Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study
DF Archer, EA Stewart, RI Jain, RA Feldman… - Fertility and …, 2017 - fertstert.org
Objective To evaluate the safety and efficacy of elagolix vs. placebo and elagolix with low-
dose E 2/progestogen add-back therapy. Design Proof-of-concept, dose-ranging, multiple …
dose E 2/progestogen add-back therapy. Design Proof-of-concept, dose-ranging, multiple …
Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study
DF Archer, EA Stewart, RI Jain, RA Feldman… - Fertility and …, 2017 - hero.epa.gov
OBJECTIVE: To evaluate the safety and efficacy of elagolix vs. placebo and elagolix with low-
dose E2/progestogen add-back therapy. DESIGN: Proof-of-concept, dose-ranging, multiple …
dose E2/progestogen add-back therapy. DESIGN: Proof-of-concept, dose-ranging, multiple …
[引用][C] Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study
DF Archer, EA Stewart, RI Jain, RA Feldman… - Fertility and …, 2017 - cir.nii.ac.jp
Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids:
results from a phase 2a proof-of-concept study | CiNii Research CiNii 国立情報学研究所 学術 …
results from a phase 2a proof-of-concept study | CiNii Research CiNii 国立情報学研究所 学術 …
Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
DF Archer, EA Stewart, RI Jain, RA Feldman… - Fertility and …, 2017 - europepmc.org
Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids:
results from a phase 2a proof-of-concept study. - Abstract - Europe PMC Sign in | Create an …
results from a phase 2a proof-of-concept study. - Abstract - Europe PMC Sign in | Create an …
Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study
DF Archer, EA Stewart, RI Jain… - Fertility and …, 2017 - pubmed.ncbi.nlm.nih.gov
Objective To evaluate the safety and efficacy of elagolix vs. placebo and elagolix with low-
dose E 2/progestogen add-back therapy. Design Proof-of-concept, dose-ranging, multiple …
dose E 2/progestogen add-back therapy. Design Proof-of-concept, dose-ranging, multiple …